Nicolas Girard, MD, PhD

Articles by Nicolas Girard, MD, PhD

Nicolas Girard, MD, PhDASCO 2024: Focus on Lung Cancer | June 12, 2024
The phase 2 trial evaluated subcutaneous amivantamab and lazertinib as a first-line therapy for EGFR-mutated NSCLC.
View More